Acadian Asset Management
VRDN icon

Acadian Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Acadian Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,919
Closed -$276K – 2267
2025
Q4 		$276K Buy
+8,919
New +$245K ﹤0.01% 1452
2020
Q3 		– Sell
-4,278
Closed -$71K – 2372
2020
Q2 		$71K Buy
+4,278
New +$48.6K ﹤0.01% 1812
2019
Q2 		– Sell
-865
Closed -$36K – 2054
2019
Q1 		$36K Buy
+865
New +$39.1K ﹤0.01% 1739
2017
Q1 		– Sell
-15
Closed -$1K – 1782
2016
Q4 		$1K Buy
+15
New +$1.57K ﹤0.01% 1603

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management's VRDN Position: Q1 2026 in Review

Acadian Asset Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 8,919 shares — an estimated $276K sold.

Acadian Asset Management first reported a position in VRDN in Q4 2016 and held it in 4 quarters. The position peaked at $276K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Acadian Asset Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 8,919 Viridian Therapeutics shares in Q1 2026, an estimated $276K.
  • Acadian Asset Management first reported a position in Viridian Therapeutics in Q4 2016 and held it in 4 quarters.
  • Acadian Asset Management's Viridian Therapeutics position peaked at $276K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.